SCHEMBL10407271

SCHEMBL10407271

Cc1cc([S])n2ncc(C)c2n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 12/20 0.41
MAPT P10636 11/20 0.38
RAB9A P51151 9/20 0.38
NPC1 O15118 8/20 0.38
SMN1; SMN2 Q16637 6/20 0.38
L3MBTL1 Q9Y468 4/20 0.38
ALDH1A1 P00352 8/20 0.37
HPGD P15428 6/20 0.37
HSD17B10 Q99714 6/20 0.37
MEN1 O00255 4/20 0.37
KMT2A Q03164 4/20 0.37
MAPK1 P28482 4/20 0.37
TP53 P04637 3/20 0.37
ALOX15 P16050 1/20 0.37
TSHR P16473 1/20 0.37
GFER P55789 1/20 0.37
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8288618 0.80 KDM4E (0.61) KDM4EMAPTRAB9ANPC1SMN1; SMN2
SCHEMBL9822430 0.78 PDE2A (0.42) KDM4EMAPTRAB9ANPC1SMN1; SMN2
SCHEMBL10407365 0.78 KDM4E (0.71) KDM4EMAPTSMN1; SMN2ALDH1A1HPGD
SCHEMBL10407273 0.77 KDM4E (0.41) KDM4EMAPTRAB9ANPC1SMN1; SMN2
SCHEMBL19455177 0.77 MAPT (0.59) KDM4EMAPTRAB9ANPC1SMN1; SMN2
SCHEMBL26253982 0.74 TYK2 (0.45) KDM4EMAPTRAB9ANPC1SMN1; SMN2
SCHEMBL12697196 0.73 HPGD (0.54) KDM4EMAPTSMN1; SMN2ALDH1A1HPGD
SCHEMBL21200356 0.72 KDM4E (0.55) KDM4EMAPTRAB9ANPC1SMN1; SMN2
SCHEMBL11962837 0.72 HSD17B10 (0.64) KDM4EMAPTRAB9ANPC1SMN1; SMN2
SCHEMBL11962825 0.70 KMT2A (0.48) KDM4EMAPTRAB9ANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4966900-A FOR MICROBISM THERAPY, BACTERIAL INFECTIONS SANKEI PHARMACEUTICAL COMPANY LTD. (JP) 1990-10-30 US disclosed
EP-0254495-A2 Beta-Lactam compound, method for preparing the same, medicinal composition for bacterially infectious disease therapy containing the same and intermediates for synthesis of the same SANKEI PHARMACEUTICAL COMPANY LIMITED (JP) 1988-01-27 EP disclosed